The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Role of Systemic Inflammatory Response in Predicting Survival in Patients with Primary Operable Cancer
Abstract
Disease progression in cancer is dependent on the complex interaction between the tumor and the host inflammatory response. There is substantial evidence in advanced cancer that host factors, such as weight loss, poor performance status and the host systemic inflammatory response, are linked, and the latter is an important tumor-stage-independent predictor of outcome. Indeed, the systemic inflammatory response, as evidenced by an elevated level of C-reactive protein, is now included in the definition of cancer cachexia. This review examines the role of the systemic inflammatory response in predicting survival in patients with primary operable cancer. Approximately 80 studies have evaluated the role of the systemic inflammatory response using biochemical or hematological markers, such as elevated C-reactive protein levels, hypoalbuminemia or increased white cell, neutrophil and platelet counts. Combinations of such factors have been used to derive simple inflammation-based prognostic scores, such as the Glasgow Prognostic Score, the neutrophil:lymphocyte ratio and the platelet:lymphocyte ratio. This review demonstrates that there is now good evidence that preoperative measures of the systemic inflammatory response predict cancer survival, independent of tumor stage, in primary operable cancer. The evidence is particularly robust in colorectal (including liver metastases), gastro-esophageal and renal cancers. As described in this article, measurement of the systemic inflammatory response is simple, reliable and can be clinically incorporated into current staging algorithms. This will provide the clinician with a better prediction of outcome, and therefore better treatment allocation in patients with primary operable cancer. Furthermore, systemic inflammation-based markers and prognostic scores not only identify patients at risk, but also provide well-defined therapeutic targets for future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
Systemic inflammation, nutritional status and survival in patients with cancer
McMillan, D. C. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a7902 · Cited by 1,001
Self-citationNeutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer
Walsh, S. R., Cook, E. J., Goulder, F., Justin, T. A., & Keeling, N. J. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20329 · Cited by 894
Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., & Dunlop, D. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601242 · Cited by 792
Self-citationCachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
Research works printed but not linked: 38
- 10.1016/0959-8049(94)90417-0 · doi:10.1016/0959-8049(94)90417-0
- 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO;2-9 · doi:10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9
- Wilop S , CrysandtM, BendelM, MahnkenAH, OsiekaR, JostE: Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.Onkologie31(12), 665–670 (2008).
- 10.1002/jso.2930360302 · doi:10.1002/jso.2930360302
- 10.1016/j.lungcan.2008.04.011 · doi:10.1016/j.lungcan.2008.04.011
- 10.1016/S0748-7983(96)92398-7 · doi:10.1016/s0748-7983(96)92398-7
- 10.1038/sj.bjc.6604926 · doi:10.1038/sj.bjc.6604926
- 10.1038/bjc.1983.198 · doi:10.1038/bjc.1983.198
- 10.1111/j.1365-3083.1984.tb00919.x · doi:10.1111/j.1365-3083.1984.tb00919.x
- Tartter PI : Pretreatment prognostic factors in colorectal cancer patients with synchronous liver metastases.Eur. J. Surg. Oncol.13(6), 485–491 (1987).
- 10.1002/jso.21294 · doi:10.1002/jso.21294
- 10.1002/cncr.20976 · doi:10.1002/cncr.20976
- 10.3748/wjg.v12.i34.5495 · doi:10.3748/wjg.v12.i34.5495
- 10.1016/S0002-9610(01)00684-5 · doi:10.1016/s0002-9610(01)00684-5
- 10.1002/jso.10275 · doi:10.1002/jso.10275
- 10.1111/j.1442-2050.2005.00474.x · doi:10.1111/j.1442-2050.2005.00474.x
- 10.3748/wjg.v12.i23.3746 · doi:10.3748/wjg.v12.i23.3746
- 10.1159/000094562 · doi:10.1159/000094562
- Suzuki K , AiuraK, KitagouMet al.: Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients.Hepatogastroenterology51(57), 847–853 (2004).
- 10.1038/sj.bjc.6602305 · DOI
- Menczer J , SchejterE, GevaD, GinathS, ZakutH: Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival.Eur. J. Gynaecol. Oncol.19(1), 82–84 (1998).
- 10.1016/S0301-2115(98)00227-9 · doi:10.1016/s0301-2115(98)00227-9
- 10.1016/j.ygyno.2003.09.002 · doi:10.1016/j.ygyno.2003.09.002
- 10.1016/S0002-9378(94)70225-X · doi:10.1016/s0002-9378(94)70225-x
- 10.1159/000093905 · doi:10.1159/000093905
- 10.1159/000112601 · doi:10.1159/000112601
- 10.1111/j.1464-410X.2007.07408.x · doi:10.1111/j.1464-410x.2007.07408.x
- 10.1111/j.1442-2042.1998.tb00380.x · doi:10.1111/j.1442-2042.1998.tb00380.x
- 10.1016/S0022-5347(05)64453-9 · doi:10.1016/s0022-5347(05)64453-9
- 10.1097/00008469-200206000-00008 · doi:10.1097/00008469-200206000-00008
- 10.1016/j.urology.2003.10.039 · doi:10.1016/j.urology.2003.10.039
- 10.1111/j.1442-2042.2006.01563.x · doi:10.1111/j.1442-2042.2006.01563.x
- 10.1016/S0022-5347(05)00526-4 · doi:10.1016/s0022-5347(05)00526-4
- 10.1111/j.1464-410X.2006.06437.x · doi:10.1111/j.1464-410x.2006.06437.x
- 10.1111/j.1464-410X.2006.06497.x · doi:10.1111/j.1464-410x.2006.06497.x
- 10.1111/j.1464-410X.2007.06934.x · doi:10.1111/j.1464-410x.2007.06934.x
- 10.1159/000106322 · doi:10.1159/000106322
- 10.1016/j.juro.2008.10.156 · doi:10.1016/j.juro.2008.10.156
Cited by
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Self-citationCancer cachexia: understanding the molecular basis
Argilés, J. M., Busquets, S., Stemmler, B., & López-Soriano, F. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3829 · Cited by 1,517
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Self-citationFranceschi, C., Garagnani, P., Vitale, G., Capri, M., & Salvioli, S. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.09.005 · Cited by 997
Proctor, M. J., Morrison, D. S., Talwar, D., Balmer, S. M., Fletcher, C. D., O’Reilly, D. S. J., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.028 · Cited by 757
Self-citationTempleton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases
Gasparyan, A. Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M., & Kitas, G. D. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.4.345 · Cited by 607
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Proctor, M. J., Morrison, D. S., Talwar, D., Balmer, S. M., O'Reilly, D. S. J., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606087 · Cited by 531
Self-citationStotz, M., Gerger, A., Eisner, F., Szkandera, J., Loibner, H., L Ress, A., Kornprat, P., A Zoughbi, W., Seggewies, F. S., Lackner, C., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.332 · Cited by 490
Li, M.-X., Liu, X.-M., Zhang, X.-F., Zhang, J.-F., Wang, W.-L., Zhu, Y., Dong, J., Cheng, J.-W., Liu, Z.-W., Ma, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28536 · Cited by 459
Chua, W., Charles, K. A., Baracos, V. E., & Clarke, S. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.100 · Cited by 468
Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K., Fushiya, N., Koike, K., Nishino, H., & Matsushima, M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4048-0 · Cited by 442
Kwon, H.-C., Kim, S. H., Oh, S. Y., Lee, S., Lee, J. H., Choi, H.-J., Park, K.-J., Roh, M. S., Kim, S.-G., Kim, H.-J., et al. (2012) · Biomarkers · doi:10.3109/1354750x.2012.656705 · Cited by 409
Cancer and systemic inflammation: treat the tumour and treat the host
Roxburgh, C. S. D., & McMillan, D. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.90 · Cited by 368
Self-citationFroessler, B., Palm, P., Weber, I., Hodyl, N. A., Singh, R., & Murphy, E. M. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001646 · Cited by 352
Koh, C.-H., Bhoo-Pathy, N., Ng, K.-L., Jabir, R. S., Tan, G.-H., See, M.-H., Jamaris, S., & Taib, N. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.183 · Cited by 327
Sharaiha, R. Z., Halazun, K. J., Mirza, F., Port, J. L., Lee, P. C., Neugut, A. I., Altorki, N. K., & Abrams, J. A. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1754-8 · Cited by 325
Paramanathan, A., Saxena, A., & Morris, D. L. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2013.12.001 · Cited by 316
Inter-tissue communication in cancer cachexia
Argilés, J. M., Stemmler, B., López-Soriano, F. J., & Busquets, S. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0123-0 · Cited by 305
Dolan, R. D., Lim, J., McSorley, S. T., Horgan, P. G., & McMillan, D. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16955-5 · Cited by 300
Self-citationFest, J., Ruiter, R., Ikram, M. A., Voortman, T., van Eijck, C. H. J., & Stricker, B. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-28646-w · Cited by 297
Pichler, M., Hutterer, G. C., Stoeckigt, C., Chromecki, T. F., Stojakovic, T., Golbeck, S., Eberhard, K., Gerger, A., Mannweiler, S., Pummer, K., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.28 · Cited by 275
Feng, J.-F., Huang, Y., & Chen, Q.-X. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-58 · Cited by 267
Aziz, M. H., Sideras, K., Aziz, N. A., Mauff, K., Haen, R., Roos, D., Saida, L., Suker, M., van der Harst, E., Mieog, J. S., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002660 · Cited by 259
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study
Villaseñor, A., Flatt, S. W., Marinac, C., Natarajan, L., Pierce, J. P., & Patterson, R. E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0852 · Cited by 89
Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015) · Oncology · doi:10.1159/000381065 · Cited by 36
Dolan, R. D., Maclay, J. D., Abbass, T., Colville, D., Buali, F., MacLeod, N., McSorley, S. T., Horgan, P. G., & McMillan, D. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-77269-7 · Cited by 22
Self-citationA review of canakinumab and its therapeutic potential for non-small cell lung cancer
Schenk, K. M., Reuss, J. E., Choquette, K., & Spira, A. I. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000832 · Cited by 22
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer
Ribnikar, D., Stukalin, I., Bedard, P. L., Hamilton, R. J., Jewett, M., Warde, P., Chung, P., Anson-Cartwright, L., Templeton, A. J., Amir, E., et al. (2020) · Current Oncology · doi:10.3390/curroncol28010014 · Cited by 15
Metadata
- Authors
- Roxburgh, C. S., & McMillan, D. C.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2009-12-18
- Volume
- 6
- Issue
- 1
- Pages
- 149-163
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2139778116
- Cited by
- 998
- References
- 93
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.